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We investigated the changes in bladder function resulting from bladder outlet obstruc-
tion (BOO), with particular emphasis on the role of nitric oide (NO) in bladder response.
Twelve-week-old female Wistar rats (n = 36) were surgically treated in various ways by
dividing them into 6 groups each with 6 animals:  2 sham-operated groups, 2 obstructed
groups for 1 week or 6 weeks, and 2 groups obstructed and  intraperitoneally injected
with 150-mg/kg L-arginine once daily for 1 week or 6 weeks.  We conducted bladder
strip stimulation studies using carbachol and KCl.  Then the bladder was used for
measurement of NO synthase (NOS) activity and was also studied histologically using
immunohistochemical staining.  Bladders in the obstructed groups were significantly
heavier than in the sham-operated groups.  The mean weight of bladders in the groups
obstructed and treated with L-arginine was almost the same as that in the sham-operated
groups.  Tissue bath studies demonstrated decreased contractility in response to
cholinergic stimulation at obstruction, but contractility at obstruction was improved
by L-arginine for 1 week or 6 weeks.  NOS activity in bladder tissue was lower in the
obstructed groups than in the sham groups, and higher in the L-arginine-combined
groups than in the obstructed groups.  These results indicate that bladder dysfunction
may be improved by treatment with L-arginine.  This study suggests that increased NO
by treatment with L-arginine plays a role in improving bladder dysfunction caused by
BOO.
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Bladder outlet obstruction (BOO) is one of the
most common urological problems in elderly
men.  An increase in urinary frequency and ur-
gency are typical symptoms in the early stages
of outlet obstruction, appearing secondarily to
benign prostatic hyperplasia.  Despite the high
prevalence of BOO, the mechanisms responsi-
ble for bladder dysfunction induced by BOO re-
main poorly understood.  In an animal model,
bladder weight was significantly increased
(Saito et al., 1993a; Berggren and Uvelius, 1998;
Kim et al., 2000), and contractile response was
significantly decreased by BOO.  Some authors
have reported that detrusor mitochondrial dam-
age may explain voiding dysfunction after BOO
(Lu et al., 2000).  Other reports have found that
BOO induces reduction in blood flow (ische-
mia), and that ischemia caused by BOO induces
bladder dysfunction (Lin et al., 1995; Buttyan et
al., 1997).
Recently, several studies have revealed that
nitric oxide (NO) is an important neurotrans-
mitter and intracellular messenger that pro-
motes homeostasis in many tissues (Saito and
Miyagawa, 1999).  One of the most important
effects of NO is reported to be its role as a neuro-
transmitter in non-adrenergic non-cholinergic
nerves, and the L-arginine-NO pathway has
been shown to play a role in muscle relaxation
and vasodilation (Arthur and Burnett, 1995).
NO stimulates the formation of guanylate cy-
clase in smooth muscle cells, converting GTP to
3' 5'-cyclic GMP (cGMP) (Burnett, 1997).  A cas-
cade of cGMP-dependent intracellular events
K. Yanagi
20
then leads to a decrease in intracellular calcium,
ultimately causing smooth muscle relaxation
and vasodilation, in part through changes in
potassium conductance (Seftel et al., 1996;
Burnett, 1997).  Recently, it has been reported
that NO is induced by ischemia injury (Saito
and Miyagawa, 1999), and that NO synthase
(NOS) isoform activity, that is, inducible NOS
(iNOS) activity, was decreased in long-term ob-
struction for 5 weeks (Lemack et al., 1999).
On the other hand, NOS activity did not
show significant changes in short-term obstruc-
tion (Shabsigh et al., 2000).  These results may
suggest that bladder dysfunction caused by
BOO is associated with loss of physiological ef-
fects of NO.
In this study, we investigated the effect of
NO on bladder dysfunction caused by BOO
with organ bath techniques.  Further, we mea-
sured NOS activity in bladder tissue and studied
immunohistochemical staining.  The aim of this
study was to determine whether or not the blad-
der dysfunction was due to BOO by treatment
with L-arginine.
Materials and Methods
Animal model
All animal experiments were performed in ac-
cordance with the guidelines set out by the
Tottori University Committee for Animal Experi-
mentation.  Twelve-week-old female Wistar
rats, mean body weight 218 g, were used (n =
36) (SLC, Shizuoka, Japan).  The 36 rats were
anesthetized with intraperitoneal (i.p.) admini-
stration of 50-mg/kg sodium pentobarbital.  Out
of the 36 rats, 24 were used as models for partial
obstruction as follows.  With the rat in the spi-
nal position after a midline suprapubic incision,
the urethra was exposed without damaging the
bladder neck and urethra.  A 2-0 silk suture was
passed behind the urethra and the catheter was
put on the urethra.  Subsequently, the urethra
and catheter were ligated and the catheter was
removed.  The presence of the catheter ensured
that the ligature did not significantly compress
the urethra.  The outside diameter of each cath-
eter was approximately 1.70 mm for obstruc-
tion (mild obstruction) (Saito et al., 1993b).  Fi-
nally, the incision was closed.  The remaining 12
rats were used for the sham operation.  Sham-
operated rats underwent a similar procedure
with a dissection around the urethra, but with-
out a urethral ligature.  After the operation, the
animals were divided into 6 groups each with 6
rats:  Group C-1, 1 week after sham operation;
Group C-6, 6 weeks after sham operation;
Group OB-1, 1-week obstruction; Group OB-6,
6-week obstruction; Group Ar-1, 1-week ob-
struction with i.p. administration of 150-mg/kg
L-arginine once daily for 1 week and Group Ar-
6, 6-week obstruction with i.p. administration
of 150-mg/kg L-arginine once daily for 6
weeks.  The rats who underwent the operation
were anesthetized, and in 1-week-treated rats
(Groups C-1, OB-1 and Ar-1), bladders were
removed on the 8th day from induction of the
operation.  In 6-week-treated rats (Groups C-6,
OB-6 and Ar-6), bladders were removed on the
43rd day from induction of the operation.  The
removed bladder specimens were weighed and
immediately used for the strip study, measure-
ment of NOS activity and histological examina-
tion.
Measurement of contractile response
Each rat was anesthetized with an i.p. injection
of 50-mg/kg sodium pentobarbital, and the uri-
nary bladder was removed as low on the urethra
as possible.  After measuring the bladder weight,
the bladder dome was immediately separated
from the bladder base at the level of the ureteral
orifices, and was separated into longitudinal
strips.  The muscle strips (5 × 1.5 mm) were sus-
pended in organ baths containing a 3.0-mL Krebs-
Henseleit’s solution at 37˚C.  The tissues were
equilibrated with a mixture of 95% O2 and 5%
CO2.  Isometric force was monitored with a TB-
612T transducer (Nihon Koden, Tokyo, Japan)
and processed by a MacLab multiport controller
(AD Instruments Japan, Tokyo).  Contractile
response to carbachol was expressed as force per
cross-sectional area of muscle (grams per square
millimeter).  Cumulative dose-response curves
were constructed in a stepwise manner after the
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response to the previous concentration had
reached a plateau.  Contractile response of the
same muscle strips to 100-mmol/L KCl was
also monitored.
Muscle NOS activity
Bladder dome tissues were homogenized in
homogenization buffer containing phosfate-
buffered saline, pH 7.4.  Homogenates were
centrifuged at 4˚C for 20 min at 10,000 × g, and
the next supernatant solutions were ultracentri-
fuged at 4˚C for 15 min at 100,000 × g.  Filtration
of the 10,000 × g supernatant through a 0.45-µ
filter prior to ultrafiltration can increase the
ultrafiltration rate.  Up to 40 µL of a sample was
added to each sample well for the microtiter
plate, then 10 µL of freshly NADPH solution (1
mmol/L) and 10 µL of nitrate reductase solution
were added to each well.  After incubating at
room temperature for 60 min, 10 µL of the co-
factor solution and 10 µL of the lactate dehy-
drogenase solution were added to each well.
This was followed by incubation at room tem-
perature for 20 min, and then a 100-µL Griess
reagent was added to each well.  Finally, a
model 550 microplate reader (Bio-Rad Labo-
ratories, Hercules, CA) was used to read the ab-
sorbance at 540 nm.  The values were estimated
per tissue weight and per amount of protein in
the tissue.  Protein was determined using a com-
mercial kit (BCA Protein Assay Reagent Kit,
Pierce, Rockford, IL).
Histological examination of the rat blad-
der
Morphological changes in the rat bladder were
studied by light microscopy.  The rat bladder
dome of each group was immediately removed
and fixed with 3.7% formaldehyde-saline.  After
fixation, the tissues were embedded in paraffin.
Sections (5 µm) were stained with hematoxylin
and eosin.  The serial sections were also sub-
jected to immunohistochemical staining for
endothelial NOS (eNOS) and iNOS.  In brief,
deparaffinized sections were retrieved using
DAKO Target Retrieval Solution and a DAKO
LSAB Kit (Carpenteria, CA).  They were then re-
acted with rabbit anti-eNOS or -iNOS polyclonal
antibody (Chemicon, Temecula, CA) at a 1:200
dilution overnight at 4˚C.  The specifically
bound 1st antibodies were visualized by bio-
tinylated horse anti-rabbit secondary antibody
(1:200 dilution) with a Histofine SAB-PO (G)
Kit (Nichirei Co., Tokyo).  Mayer’s hematoxylin
was used for counterstaining.  Negative con-
trols were established for each group according
to the procedure mentioned above, but without
2nd antibodies.
Data analysis
Contractile data were calculated as grams of ac-
tive force per cross-sectional area in millime-
ters.  The cross-sectional area was calculated
using the following equation:
     cross-sectional area = weight/(length × 1.05),
where 1.05 is the assumed density of the muscle.
The dose ratio was obtained from the ratio of me-
dian effective dose (ED50) values (the concentra-
tion of agonist that produces a half-maximal con-
tractile response) for carbachol.  ED50 values
were calculated as geometric means, whereas
maximum effective dose (Emax) values were cal-
culated as arithmetic means.  NOS activity was
calculated as follows:
     NOS activity = {(A540 – b)/m}(200/40)/60,
where A540 is the sample absorbance at 540
nm, b is the y-intercept, m is the slope, 200 is
the final volume, 40 is the sample volume, and
60 is the NOS reaction incubation time in min-
utes.  Statistical comparison of differences be-
tween groups was performed using analysis of
variance and Fisher’s test for the multiple com-
parison; P < 0.05 was regarded as the level of
significance.
Drugs and chemicals
L-arginine, carbachol and pentobarbital were
purchased from Sigma (St. Louis, MO).  DAKO
Target Retrieval Solution and the DAKO LSAB
Kit were from DAKO.  Polyclonal antibodies
against eNOS and iNOS were from Chemicon.
The Histofine SAB-PO (G) Kits were from
K. Yanagi
22
Table 1.  Bladder weight
         Group Bladder weight
[number of animals] (g)
C-1 [6] 0.109 ± 0.005
OB-1 [6] 0.174 ± 0.024
Ar-1 [6] 0.136 ± 0.012
C-6 [6] 0.114 ± 0.006
OB-6 [6] 0.242 ± 0.035
Ar-6 [6] 0.149 ± 0.012
Bladder weight data are shown as mean ± SEM in
each group.
Ar, L-arginine-dosed; C, sham-operated; OB, ob-
structed.
* P < 0.05.
Table 2.  Functional data of obstructed rat bladders
          Group Emax ED50 100-mmol/L KCl
[number of animals] (g/mm2) (µmol/L) (g/mm2)
C-1 [6]   9.89 ± 0.88 1.60 ± 0.15 6.96 ± 0.91
OB-1 [6]   4.27 ± 0.52 0.89 ± 0.14 2.12 ± 0.26
Ar-1 [6]   8.93 ± 0.84 1.82 ± 0.26 5.93 ± 0.60
C-6 [6] 11.38 ± 0.57 2.11 ± 0.54 8.53 ± 0.58
OB-6 [6]   4.61 ± 0.38 1.30 ± 0.21 3.09 ± 0.29
Ar-6 [6]   6.79 ± 0.32 1.71 ± 0.43 4.85 ± 0.30
Emax and ED50 are for carbachol.  Data are shown as mean ± SEM in each group.
Ar, L-arginine-dosed; C, sham-operated; OB, obstructed.
* P < 0.05.
Nichirei.  The NOS activity assay kit was from
OXIS International, Inc. (Portland, OR).  The
BCA Protein Assay Reagent Kit was from
Pierce.  All other chemicals were of reagent
grade.
Results
Bladder weight
Bladder weight was significantly increased by
obstruction.  For the long-term groups, the
mean bladder weight at 6 weeks of obstruction
was increased 2-fold compared to that in the
sham-operated group.  However, the mean
bladder weight at 6 weeks of obstruction with
treatment by L-arginine was almost the same as
that in the sham-operated group.  The tendency
in the 1-week groups was similar to that in the
6-week groups (Table 1).
Contractile response to carbachol and
KCl
Concentration-dependent contractile responses
of bladder strips to carbachol are shown in
Table 2, together with their Emax and ED50 val-
ues summarized.  At both 1 week and 6 weeks,
the obstructed groups showed significantly
lower Emax and ED50 values than the sham-
operated groups.  Contractility of bladder mus-
cles of rats receiving L-arginine significantly
recovered compared to that in the obstructed
groups, but was not equal to that in the sham-
operated groups.  Contractile response induced
by 100-mmol/L KCl showed a pattern parallel
to those of Emax values of carbachol in each
group.
Muscle NOS activity
At 1 week and 6 weeks, NOS activity was re-
duced in the obstructed groups as compared to
the sham-operated groups, and was increased in
the L-arginine groups as compared to the ob-
structed groups.  But there was no significant
difference among the groups (Table 3).
Histological changes in rat bladders by
chemicals
A representative light microscopic photograph
of the bladder from an L-arginine-dosed rat is
shown in Fig. 1 and another from an obstructed
rat in Fig. 2.  Figure 1 shows eNOS positive in
*
*
*
*
*
*
*
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*
*
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the mucosal region, vessels and
smooth muscle region.  In Fig. 2,
iNOS is detected in the mucosal
region, and positive in the infiltrated
leukocytes.  eNOS and iNOS were
detected in all groups in the same
manner.
Table 3.  NOS activity in the rat bladder
           Group                NOS activity
[number of animals]             (nmol/ng protein/min)
C-1 [6] 0.063 ± 0.004
OB-1 [6] 0.049 ± 0.005
Ar-1 [6] 0.063 ± 0.012
C-6 [6] 0.105 ± 0.016
OB-6 [6] 0.068 ± 0.013
Ar-6 [6] 0.079 ± 0.012
NOS activity data are shown as mean ± SEM in each group.
Ar, L-arginine-dosed; C, sham-operated; OB, obstructed.
Fig. 1.  Sections of rat bladder tissue from the L-arginine-dosed group in 6-week-immunostained by anti-
endothelial nitric oxide synthase (eNOS) antibodies (× 100).
Fig. 2.  Sections of rat bladder tissue from the obstructed group in 6-week-immunostained by anti-inducible
nitric oxide synthase (iNOS) antibodies (× 200).
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Discussion
Several authors have postulated that obstruction-
induced ischemia is responsible for the bladder
dysfunction seen with BOO (Lin et al., 1995;
Buttyan et al., 1997).
Our data demonstrated that BOO increased
bladder weight and decreased contractility in
response to carbachol and KCl.  Bladder weight
significantly increased in a 1- or  6-week outlet
obstruction.  But by treatment with L-arginine,
bladder weight did not significantly increase
compared to that in the sham-operated groups.
The carbachol-induced developed tension was
decreased by BOO.  The contractile response
recovered by treatment with L-arginine.  In add-
ition, we measured NOS activity in the experi-
mentally obstructed bladders.  At 6 weeks of
obstruction, NOS activity was decreased by the
obstruction, and was increased by treatment
with L-arginine.  But there was no significant
difference among the groups.  In the histologi-
cal examination, there were no distinct differ-
ences in immunohistochemical staining among
the groups.  eNOS was positive in the mucosal
region, vessels and smooth muscle region, and
iNOS was detected in the mucosal region and in
the infiltrated leukocytes in the bladder dome.
These data indicate that bladder function may
not to be associated with NOS activity.  But
treatment with L-arginine may increase NO,
which may improve bladder function.
Bladder distention caused by BOO induces
ischemic changes in the bladder (Lin et al., 1995).
The ischemia caused by BOO temporarily in-
creases NO concentration in the bladder for short-
term obstruction (Saito and Miyagawa, 2001);
however, NO is gradually decreased for long-
term obstruction, and the decrease in NO in-
duces bladder dysfunction.  It is reported that
NO is a mediator of relaxation of the urethra in
rats (Mumtaz et al., 2000), and that, as a result,
the load of the bladder is reduced.  The rat de-
trusor is reported to be capable of responding to
NO (Chung et al., 1996).  NO induces vasodila-
tion, and the released NO maintains the neces-
sary blood supply via the circulatory system by
dilating arteries (Saito and Miyagawa, 1999),
which may play a role in relaxing of the detrusor.
Increased levels of NO treated with L-arginine
may relax the urethra and decrease the load of
the bladder, and recover the blood flow.
Histochemical examination revealed that a
brain subtype of NOS (bNOS) was distributed
in the proximal urethra of the dog (Takeda and
Lepor, 1995), and in the rat bladder neck and
urethra (Tamaki et al., 1995).  Upon distribu-
tion of NOS in the bladder dome, our data de-
monstrated that eNOS was positive in the mu-
cosal region, vessels and smooth muscle re-
gion, and that iNOS was detected in the muco-
sal region and the infiltrated leukocytes in the
bladder dome, as was reported before (Saito
and Miyagawa, 1999; Persson et al., 1999).
These observations  indicate that vasodilation
and detrusor relaxation may be induced by
treatment with L-arginine.  As there is no sig-
nificant difference in NOS activity in these
groups, treatment with L-arginine increases NO
in the bladder.
As a result, L-arginine prevents an increase
in bladder weight and a decrease in the con-
tractile response:  that is, L-arginine prevents
the bladder dysfunction caused by BOO.  Be-
cause of this, the reasons for the results obtain-
ed in this experiment are speculated as follows:
i) Experimentally obstructed bladder outlets in
the rats induced bladder overload and ischemia,
and resulted in an increase in bladder weight
and bladder dysfunction;  ii) Treatment by L-
arginine increased NO in the urethra and blad-
der, decreased bladder overload and increased
the blood flow of the bladder by vasodilation.
These changes resulted in a decrease in bladder
weight and recovery from bladder dysfunction.
The present findings reveal the possibility
that bladder dysfunction caused by BOO is im-
proved by treatment with L-arginine, which
may increase NO concentration.
However, Saito et al. (1998) reported that
reperfusion following ischemia causes more
severe dysfunction than that of ischemia alone
in the rat bladder.  Reactive oxygen species,
such as the superoxide radical, hydroxyl radical
and hydrogen peroxide, are known to induce in-
jury in several tissues.  The generation of these
reactive oxygen species is attributed to ische-
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mia-reperfusion injury.  These reactive oxygen
species damage many biological molecules.  Per-
oxynitrate, reacting with NO and superoxide
radicals, is also reported to be a powerful oxida-
tive product (Muijsers et al., 1997).  Saito and
Miyagawa (1999) offered the idea that peroxy-
nitrate reacting with NO and superoxide radi-
cals may be involved in ischemia-reperfusion
injury in the bladder.  In their reports, NO and
peroxynitrate induce bladder dysfunction, a
finding which indicates that NO has a cytotoxic
effect in the experimentally obstructed bladder.
However, our presented data demonstrated that
NO has a cytoprotective effect in the bladder.
Therefore, NO has both damaging and protec-
tive effects in many tissues.
In summary, i) bladder weight was increas-
ed by BOO, and the increase in bladder weight
could be restrained by treatment with L-argi-
nine; ii) the carbachol-induced developed ten-
sion was decreased by BOO, and was recovered
with treatment by L-arginine; and iii) in the his-
tological studies, eNOS was positive in the
mucosal region, vessels and smooth muscle re-
gion, and iNOS was positive in the mucosal re-
gion and in the infiltrated leukocytes.  It is sug-
gested that treatment with L-arginine may
improve the bladder dysfunction caused by BOO.
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